Women Less Likely to Fill Post-MI Statin Prescription
MONDAY, April 16, 2018 -- Women are less likely than men to fill a prescription for high-intensity statins after hospitalization for myocardial infarction (MI), according to a study published in the April 24 issue of the Journal of the American College of Cardiology.
Sanne A.E. Peters, Ph.D., from the University of Oxford in the United Kingdom, and colleagues evaluated sex differences in prescription fills for high-intensity statin therapy after MI, overall and across population subgroups. Data from the MarketScan database (16,898 U.S. adults <65 years with commercial health insurance) and Medicare (71,358 U.S. adults ≥66 years) were used.
The researchers found that 56 percent of men and 47 percent of women filled a high-intensity statin prescription after hospital discharge for MI. Women were less likely to fill a high-intensity statin than men overall (adjusted risk ratio [RR], 0.91), among those with no prior statin use (adjusted RR, 0.91), among those taking low/moderate-intensity statins prior to MI (adjusted RR, 0.87), and among those taking high-intensity statins prior to their MI (adjusted RR, 0.98). Women were less likely than men to fill high-intensity statins within all subgroups analyzed, although the disparity was greatest in the youngest and oldest adults and for those without prevalent comorbid conditions.
"Despite recent efforts to reduce sex differences in guideline-recommended therapy, women continue to be less likely than men to fill a prescription for high-intensity statins following hospitalization for MI," the authors write.
Several authors disclosed financial ties to the pharmaceutical industry, including Amgen, which partially funded the study.
© 2020 HealthDay. All rights reserved.
Posted: April 2018
More News Resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
- Monthly Update Archive
Subscribe to our Newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.